Recellularization is a transformative process in tissue engineering that involves repopulating a decellularized tissue scaffold with living cells to restore its structure and function. Decellularization is the initial step, where cells are removed from a tissue or organ, leaving behind a three-dimensional extracellular matrix. This acellular matrix retains the tissue's architecture, mechanical properties, and signaling cues. Recellularization follows, where the acellular scaffold is infused with the desired cell types, such as stem cells or differentiated cells, allowing them to adhere, proliferate, and differentiate within the matrix. The goal is to create functional, bioengineered tissues that closely mimic native structures. Recellularization has been applied to various organs, including the heart, lungs, liver, and kidneys, offering potential solutions for organ transplantation shortages. This technique is not only a means to generate replacement organs but also serves as a valuable tool for drug testing, disease modeling, and understanding cell-matrix interactions. Challenges in achieving optimal recellularization include maintaining cell viability, promoting proper tissue integration, and ensuring appropriate functionality. Ongoing research continues to refine recellularization techniques, addressing these challenges and unlocking the full potential of this innovative approach in regenerative medicine.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Will be updated soon...
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : Will be updated soon...
Nagy Habib, Imperial College London, United Kingdom
Title : Will be updated soon...
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : Advanced 3D tissue models: Pioneering tools for investigating health and disease
Lucie Bacakova, Institute of Physiology of the Czech Academy of Sciences, Czech Republic
Title : Developing iPSC-derived 3D Outer Blood-Retinal Barrier Disease Models of Choroideremia for Gene Therapy Evaluation
Aradhana Kasimsetty, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), United States